CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer
References (51)
- et al.
Chemokines: a new classification system and their role in immunity
Immunity
(2000) - et al.
The functional role of the ELR motif in CXC chemokine-mediated angiogenesis
J Biol Chem
(1995) - et al.
The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer
Cytokine Growth Factor Rev
(2011) - et al.
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3
Blood
(2011) - et al.
Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C
J Biol Chem
(1997) Heparin-induced thrombocytopenia
J Thromb Haemost
(2009)- et al.
Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings
Thromb Res
(2008) - et al.
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications
Blood
(2006) - et al.
Heparin-induced thrombocytopenia: laboratory studies
Blood
(1988) - et al.
Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia
Blood
(2001)
Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin
Chest
(2002)
The temporal profile of the anti-PF4/heparin immune response
Blood
(2009)
Studies of the immune response in heparin-induced thrombocytopenia
Blood
(2009)
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)
Chest
(2008)
IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support
J Thromb Haemost
(2007)
Impact of the patient population on the risk for heparin-induced thrombocytopenia
Blood
(2000)
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital
Thromb Res
(2009)
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study
Blood
(2003)
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study
Blood
(2005)
Cancer, thrombosis and heparin-induced thrombocytopenia
Thromb Res
(2007)
Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Chest
(2012)
Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
Am J Med
(1999)
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion
J Thromb Haemost
(2010)
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings
J Thromb Haemost
(2006)
Prospective evaluation of the “4Ts” score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia
J Thromb Haemost
(2007)
Cited by (14)
Pathogenesis and management of heparin-induced thrombocytopenia and thrombosis
2020, Clinica Chimica ActaCitation Excerpt :It is produced by megakaryocytes and stored in the platelet alpha-granules. When platelets are stimulated and activated, a large quantity of PF4 will be released into the peripheral blood [41–43] to bind to the negatively charged glycosaminoglycan (GAG) chains in the platelets [44] (Fig. 1a). Then, negatively charged heparin binds to the free positive charge PF4, resulting in the changes of the configuration of the tetramer PF4 [45].
Patterns and functional implications of platelets upon tumor “education”
2017, International Journal of Biochemistry and Cell BiologyPlatelet factor 4 and its modulatory effect on systemic carcinogenesis
2013, Thrombosis ResearchSEC23A inhibit melanoma metastatic through secretory PF4 cooperation with SPARC to inhibit MAPK signaling pathway
2021, International Journal of Biological Sciences
Copyright © 2012 Elsevier Ltd. All rights reserved.